Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action
Year: 2013
Type: review
Abstract: New tuberculosis drug regimens are creating new priorities for drug susceptibility testing (DST) and surveillance. To minimise turnaround time, rapid DST will need to be prioritised, but developers of these assays will need better data about the molecular mechanisms of resistance. Efforts are underway to link mutations with drug resistance and to develop strain collections to enable assessment of new diagnostic assays. In resource-limited settings, DST might not be appropriate for all patients with tuberculosis. Surveillance data and modelling will help country stakeholders to design appropriate DST algorithms and to decide whether to change drug regimens. Finally, development of practical DST assays is needed so that, in countries where surveillance and modelling show that DST is advisable, these assays can be used to guide clinical decisions for individual patients. If combined judiciously during both development and implementation, new tuberculosis regimens and new DST assays have enormous potential to improve patient outcomes and reduce the burden of disease.
Source: The Lancet Infectious Diseases
Authors: William A Wells, Catharina C Boehme, Frank GJ Cobelens, Colleen Daniels, David Dowdy, Elizabeth Gardiner, Jan Gheuens, Peter Kim, Michael E Kimerling, Barry Kreiswirth, Christian Lienhardt, Khisi Mdluli, Madhukar Pai, Mark D Perkins, Trevor Peter, Matteo Zignol, Alimuddin Zumla, Marco Schito
Institutions: TB Alliance, FIND, Amsterdam UMC Location University of Amsterdam, Amsterdam Institute for Global Health and Development, Treatment Action Group, Johns Hopkins University, Gates Foundation, National Institutes of Health, National Institute of Allergy and Infectious Diseases, University of Medicine and Dentistry of New Jersey, World Health Organization, McGill University, Clinton Health Access Initiative, University Teaching Hospital, University of Zambia, University College London, Henry M. Jackson Foundation
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $7,280
Funders: U.S. Department of Health and Human Services, United States Agency for International Development, Bill and Melinda Gates Foundation, San Diego State University, Irish Aid, London School of Hygiene and Tropical Medicine, Department for International Development, UK Government, European Commission, Department of Science and Technology, Ministry of Science and Technology, India, National Institutes of Health, U.S. Food and Drug Administration, National Institute of Allergy and Infectious Diseases
OpenAlex ID: W2124355658
